Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2018

Dong Zhong-Yi, Zhang Chao, Li Yu-Fa, Su Jian, Xie Zhi, Liu Si-Yang, Yan Li-Xu, Chen Zhi-Hong, Yang Xue-Ning, Lin Jun-Tao, Tu Hai-Yan, Yang Jin-Ji, Zhou Qing, Sun Yue-Li, Zhong Wen-Zhao, Wu Yi-Long

Abstract excerpt

INTRODUCTION: Subtype classification of lung adenocarcinoma (LUAD) divides different survivals and therapeutic vulnerabilities; however, little is known about the disease's underlying molecular mechanism. This study sought to determine the genetic and immune profiles of histologic subtypes and identify the evidence for adjuvant immunotherapy. METHODS: We performed an integrated analysis of multidimensional data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Follow-Up Studies

Share to Gene Expression Regulation, Neoplastic

Share to Immunotherapy

Share to Lung Neoplasms

Share to Survival Rate

Source

Identifiers

PMID: 29127022
DOI: 10.1016/j.jtho.2017.10.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.PMID 29127022Read ↗

Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.Semantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene setsSemantic proximity Read ↗

Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.Semantic proximity Read ↗

Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma.Semantic proximity Read ↗

Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype.Semantic proximity Read ↗

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.Semantic proximity Read ↗

Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.Semantic proximity Read ↗

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma.Semantic proximity Read ↗

Immunogenic Cell Death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinomaSemantic proximity Read ↗

Molecular differences across invasive lung adenocarcinoma morphological subgroupsSemantic proximity Read ↗

Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung AdenocarcinomaSemantic proximity Read ↗

P53 and NLR could recognize distinct subtypes of lung adenocarcinoma with high expression of PD-L1 (TPS≥50%) defined by 22C3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.